Publicacións en colaboración con investigadores/as de Academic Medical Center (25)

2022

  1. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: Final results of the SYNTAX II study

    European Heart Journal, Vol. 43, Núm. 13, pp. 1307-1316

  2. Mild haemoglobin drop and clinical outcomes in acute coronary syndrome patients: finding from the BleeMACS registry

    Journal of Geriatric Cardiology, Vol. 19, Núm. 12, pp. 981-989

2021

  1. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

    Circulation, Vol. 144, Núm. 15, pp. 1196-1211

  2. Dual antiplatelet therapy after PCI in patients at high bleeding risk

    New England Journal of Medicine, Vol. 385, Núm. 18, pp. 1643-1655

2020

  1. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data

    EuroIntervention, Vol. 14, Núm. 16, pp. 1451-1457

  2. Antithrombotic Therapy in Patients With Prior Stroke/Transient Ischemic Attack and Acute Coronary Syndromes

    Angiology

  3. Outcome of Patients With Prior Stroke/Transient Ischemic Attack and Acute Coronary Syndromes

    Angiology, Vol. 71, Núm. 4, pp. 324-332

2019

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: Twoyear follow-up of the SYNTAX II study

    EuroIntervention, Vol. 15, Núm. 3, pp. E244-A252

  2. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial

    The Lancet, Vol. 393, Núm. 10175, pp. 987-997

2018

  1. Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry

    American Journal of Cardiovascular Drugs, Vol. 18, Núm. 4, pp. 299-309

  2. Gender-related differences in post-discharge bleeding among patients with acute coronary syndrome on dual antiplatelet therapy: A BleeMACS sub-study

    Thrombosis Research, Vol. 168, pp. 156-163

  3. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy

    European heart journal. Acute cardiovascular care, Vol. 7, Núm. 7, pp. 631-638

  4. Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)

    EuroIntervention, Vol. 14, Núm. 11, pp. E1224-E1226

  5. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

    The Lancet, Vol. 392, Núm. 10151, pp. 940-949

2017

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

    European Heart Journal, Vol. 38, Núm. 42, pp. 3124-3134

  2. Complete or incomplete coronary revascularisation in patients with myocardial infarction and multivessel disease: A propensity score analysis from the "real-life" BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registry

    EuroIntervention, Vol. 13, Núm. 4, pp. 407-414

  3. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy

    JACC: Cardiovascular Interventions, Vol. 10, Núm. 18, pp. 1867-1877

  4. Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome

    Catheterization and Cardiovascular Interventions, Vol. 90, Núm. 2, pp. E31-E37

  5. Impact of triple antithrombotic therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention in real-world practice

    Journal of Geriatric Cardiology, Vol. 14, Núm. 11, pp. 679-687

  6. Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study

    American Journal of Cardiovascular Drugs, Vol. 17, Núm. 1, pp. 61-71